Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases - Time for a New Dialogue?
J Rheumatol
.
2018 Aug;45(8):1075-1077.
doi: 10.3899/jrheum.180197.
Epub 2018 Aug 1.
Authors
William Tillett
1
,
Laura Bojke
2
Affiliations
1
Royal National Hospital for Rheumatic Diseases; and Department of Pharmacy and Pharmacology, University of Bath, Bath; w.tillett@nhs.net.
2
Centre for Health Economics, University of York, York, UK.
PMID:
30068757
DOI:
10.3899/jrheum.180197
No abstract available
Publication types
Editorial
Comment
MeSH terms
Arthritis, Psoriatic*
Biological Products*
Cost-Benefit Analysis
Humans
Rheumatic Diseases*
Synthetic Drugs
Substances
Biological Products
Synthetic Drugs